Medical Evidence
Efficacy Of Chondroprotective Agents
During Gonarthritis E. S. Tzvetkova, E. R. Agababova,
E. S. Mach and N. A. Bogomolova Institute of Rheumatology RAMS,
Moscow, Russia
Objective: To evaluate the
comparative efficacy and safety of Arthrone (chondroitin sulphate,
Moscow) and Rumalon (peptide complex of glycosoaminoglycans company
'Robapharm') we carried out a long-term randomized study in 43
patients with primary gonarthritis.
Methods: Experimental and
control groups were similar as to basic demographic, clinical
and radiological parameters. Assessment of efficacy and safety
of the two agents was performed every 6 months for 2 years applying
clinical (e.g. pain, functional Lequesne index), radioIogical
and some instrumental criteria. The latter were used for deep
analysis of articular structure and periarticular tissues, mainly
reactive synovitis. The experimental group demonstrated subsiding
pain in the knee joint (from 3.19±0.29-2.3±0.29, P < 0.05), decrease
of Lequesne index (from 3.7±0.65-1.88±0.3, P < 0.05) and reactive
synovitis (in 75% of patients). Clinical parameters in the control
group were unchanged with the exception of synovitis.
Results: Data obtained demonstrates
chondroprotective properties and safety of the studied agents.